Rosen M, Chan L, Beart R W, Vukasin P, Anthone G
Center for Colorectal Diseases, University of Southern California School of Medicine, Los Angeles 90033, USA.
Dis Colon Rectum. 1998 Sep;41(9):1116-26. doi: 10.1007/BF02239433.
The value of intensive follow-up for patients after resection of colorectal cancer remains controversial. This study reviews all randomized and prospective cohort studies to assess the value of aggressive follow-up.
The literature was searched from the years 1972 to 1996 for studies reporting on the follow-up of patients with colorectal cancer. Randomized and comparative-cohort studies that included history, physical examination, and carcinoembrionic antigen values at least three times a year for at least two years were included in a meta-analysis. Single-cohort studies with intensive follow-up and traditional follow-up were also included in a two-group comparative analysis for each outcome indicator. Outcome indicators were 1) curative resection rates after recurrent cancer, 2) survival rates of curative re-resections, 3) length of survival after recurrence, and 4) cumulative five-year survival.
Two randomized and three comparative-cohort studies met these criteria and included 2,005 patients, which were evaluated in the meta-analysis. The cumulative five-year survival was 1.16 times higher in the intensively followed group (P = 0.003). Two and one-half times more curative re-resections were performed for recurrent cancer in those patients undergoing intensive follow-up (P = 0.0001). Those patients in the intensive follow-up group with a recurrence had a 3.62-times higher survival rate than the control (P = 0.0004). Fourteen single-cohort studies were also included in the comparative analysis of 6,641 patients. The findings from these aggregated studies support the results of the meta-analysis.
Our study concludes that intensive follow-up detects more recurrent cancers at a stage amenable to curative resection, resulting in an improvement in survival of recurrences and an increased overall five-year cumulative rate of survival.
结直肠癌切除术后患者强化随访的价值仍存在争议。本研究回顾了所有随机和前瞻性队列研究,以评估积极随访的价值。
检索1972年至1996年的文献,查找有关结直肠癌患者随访的研究。纳入至少每年进行三次病史、体格检查和癌胚抗原值检测,且至少持续两年的随机和比较队列研究进行荟萃分析。单队列研究中,强化随访组和传统随访组也针对每个结局指标进行两组比较分析。结局指标包括:1)复发性癌症后的根治性切除率;2)根治性再次切除后的生存率;3)复发后的生存时长;4)累积五年生存率。
两项随机研究和三项比较队列研究符合这些标准,共纳入2005例患者,进行荟萃分析。强化随访组的累积五年生存率高出1.16倍(P = 0.003)。强化随访的患者中,因复发性癌症进行的根治性再次切除手术比对照组多2.5倍(P = 0.0001)。强化随访组中复发的患者生存率比对照组高3.62倍(P = 0.0004)。比较分析还纳入了14项单队列研究中的6641例患者。这些汇总研究的结果支持了荟萃分析的结果。
我们的研究得出结论,强化随访能在可进行根治性切除的阶段发现更多复发性癌症,从而提高复发后的生存率以及总体五年累积生存率。